SOURCE: PLC Systems, Inc.

May 02, 2013 08:00 ET

PLC Systems to Present at Taglich Brothers 10th Annual Small Cap Equity Conference

MILFORD, MA--(Marketwired - May 02, 2013) - PLC Systems Inc. (OTCQB: PLCSF), a company focused on innovative medical device technologies, today announced that it will participate in the Taglich Brothers 10th Annual Small Cap Equity Conference. The Conference will take place on Tuesday, May 7th 2013 at the New York Athletic Club. Mark R. Tauscher, President and CEO of PLC, is scheduled to present at 3:15 pm. 

The presentation will be streamed live and accessible at the time through the following link: It is recommended that you log into the site fifteen minutes in advance of the presentation. After the presentation, a webcast replay will be available on PLC's website ( by accessing the following link at The webcast will be archived on the company's website for 30 days following completion of the event.

About PLC Systems Inc.

PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. PLC must successfully complete a pivotal clinical study assessing the safety and effectiveness of RenalGuard in reducing the rates of CIN in at-risk patients and obtain U.S. Food and Drug Administration ("FDA") pre-market approval in order to market RenalGuard in the United States. The first patient was enrolled in the U.S. pivotal study in January 2012.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2012, a copy of which is on file with the SEC.

PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc.

Contact Information